EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study

Elizabeth B White iD, Lauren Grant iD, Josephine Mak iD, Lauren Olsho iD, Laura J Edwards iD, Allison Naleway iD, Jefferey L Burgess iD, Katherine D Ellingson, Harmony Tyner iD, Manjusha Gaglani iD, Karen Lutrick iD, Alberto Caban-Martinez iD und 8 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae491 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Elizabeth B White und 19 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Asymptomatic Infections, Vaccine Efficacy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Abt Associates, NCIRD CDC HHS, Marshfield Clinic Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous estimates of vaccine effectiveness (VE) against asymptomatic influenza virus infection based on seroconversion have varied widely and may be biased. We estimated 2022–2023 influenza VE against illness and asymptomatic infection in a prospective cohort.

Methods

In the HEROES-RECOVER cohort, adults at increased occupational risk of influenza exposure across 7 US sites provided weekly symptom reports and nasal swabs for reverse transcription–polymerase chain reaction (RT-PCR) influenza testing. Laboratory-confirmed influenza virus infections were classified as symptomatic (≥1 symptom) or asymptomatic during the week of testing. Participants reported demographic information and vaccination through surveys; most sites verified vaccination through medical record and immunization registry review. Person-time was calculated as days from the site-specific influenza season start (September–October 2022) through date of infection, study withdrawal, or season end (May 2023). We compared influenza incidence among vaccinated versus unvaccinated participants overall, by symptom status, and by influenza A subtype, using Cox proportional hazards regression adjusted for site and occupation. We estimated VE as (1 − adjusted hazard ratio) × 100%.

Results

In total, 269 of 3785 (7.1%) participants had laboratory-confirmed influenza, including 263 (98%) influenza A virus infections and 201 (75%) symptomatic illnesses. Incidence of laboratory-confirmed influenza illness among vaccinated versus unvaccinated participants was 23.7 and 33.2 episodes per 100 000 person-days, respectively (VE: 38%; 95% CI: 15%–55%). Incidence of asymptomatic influenza virus infection was 8.0 versus 11.6 per 100 000 (VE: 13%; 95% CI: −47%, 49%).

Conclusions

Vaccination reduced incidence of symptomatic but not asymptomatic influenza virus infection, suggesting that influenza vaccination attenuates progression from infection to illness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesAsymptomatic InfectionsVaccine EfficacyHumansProspective StudiesMaleFemaleMiddle AgedAdultAgedIncidenceUnited StatesVaccinationYoung AdultInfluenza A virus

Stichwörter der Autor:innen

asymptomatic infectioncohortinfluenzasymptomatic illnessvaccines

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.
  • Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA.
  • Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia, USA.
  • Abt Associates, Rockville, Maryland, USA.
  • Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
  • Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.

ORCID-Profile: Elizabeth B White, Lauren Grant, Josephine Mak, Lauren Olsho, Laura J Edwards, Allison Naleway, Jefferey L Burgess, Harmony Tyner, Manjusha Gaglani, Karen Lutrick, Alberto Caban-Martinez, Gabriella Newes-Adeyi, Jazmin Duque, Sarang K Yoon, Andrew L Phillips, Amadea Britton, Ashley Fowlkes

Förderung

  • Abt Associates
  • NCIRD CDC HHS
  • Marshfield Clinic Research Institute
  • University of Arizona
  • Intramural CDC HHS
  • CDC HHS
  • National Center for Immunization and Respiratory Diseases
  • Centers for Disease Control and Prevention

Zitieren

APA

White, E. B., Grant, L., Mak, J., Olsho, L., Edwards, L. J., Naleway, A., Burgess, J. L., Ellingson, K. D., Tyner, H., Gaglani, M., Lutrick, K., Caban-Martinez, A., Newes-Adeyi, G., Duque, J., Yoon, S. K., Phillips, A. L., Thompson, M., Britton, A., Flannery, B., & Fowlkes, A. (2025). Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae491

Vancouver

White EB, Grant L, Mak J, Olsho L, Edwards LJ, Naleway A, et al. Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae491

BibTeX
@article{White2025,
  author = {White, Elizabeth B and Grant, Lauren and Mak, Josephine and Olsho, Lauren and Edwards, Laura J and Naleway, Allison and Burgess, Jefferey L and Ellingson, Katherine D and Tyner, Harmony and Gaglani, Manjusha and Lutrick, Karen and Caban-Martinez, Alberto and Newes-Adeyi, Gabriella and Duque, Jazmin and Yoon, Sarang K and Phillips, Andrew L and Thompson, Mark and Britton, Amadea and Flannery, Brendan and Fowlkes, Ashley},
  title = {Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae491}
}
Kostenlos starten →